



Tranexamic Technologies
BioLabs Pegasus Park
3060 Pegasus Park Dr., Bldg 6
Dallas, Texas 75247
paul.stewart@txatech.com

Tranexamic Technologies Joins Johnson & Johnson Innovation, JLABS

Dallas, Texas (April 9, 2024) - Tranexamic Technologies is pleased to announce that it has become a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers. More information: <http://jllabs.jnjinnovation.com/>

Tranexamic Technologies is a group of pharmaceutical development companies with projects involving 1) a novel anticancer molecule, with an initial focus on triple negative breast cancer, 2) a topical gel for treatment of skin cancer, 3) a nasal spray for universal treatment and prophylaxis against respiratory viruses, a novel weapon against seasonal flu as well as emergent potential pandemics, 4) early treatment of mild traumatic brain injury (concussion), including on the battlefield and in sports settings, 5) a topical gel for reduction of bruising after nonsurgical cosmetic procedures, and 6) a potentially revolutionary safe oral medication to reduce disease and extend healthy lifespan (healthspan).

Paul Stewart, Co-Founder of Tranexamic Technologies, commented on the significance of this development for the companies: "Joining J&J Innovation will give us access to the many resources, events, and contacts of the extensive J&J Innovation ecosystem, as well as a contact point for potential partnering with the various divisions and research initiatives of J&J. This comes at an excellent time for us, as several of our projects are at the clinical trial stage or the final preclinical testing phase."



Tranexamic Technologies was co-founded by Paul Stewart and Frank Murdock, serial entrepreneurs in the biotech field who first worked together at the Leibinger companies, a global leader in craniofacial surgery and high precision neurosurgery based in Germany. After they helped sell the company to Pfizer, Stewart continued to lead the Leibinger division as well as joining the management board of Howmedica, Pfizer's \$1 billion orthopedic subsidiary, and Murdock continued to lead the global neuro division. They have been working on various aspects of the Tranexamic Technologies companies for over ten years.

Tranexamic Technologies is a member of BioLabs Pegasus Park and BioNTX and participates frequently in bioscience events in Texas as well as the national and international events of the Biotechnology Innovation Organization (BIO) and the Medical Technology Enterprise Consortium (MTEC). For more information, contact Paul Stewart:
paul.stewart@txatech.com